Ys Biopharma Co Stock Today
| YS Stock | 0.56 0.02 3.70% |
|
|
YS Biopharma is selling for under 0.56 as of the 6th of December 2023; that is 3.70 percent up since the beginning of the trading day. The stock's lowest day price was 0.52. YS Biopharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for YS Biopharma Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of November 2023 and ending today, the 6th of December 2023. Please note, there could be an existing legal relationship between YS Biopharma (YS) and Summit Healthcare (SMIH). Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of March 2023 | Category Healthcare | Classification Health Care |
YS Biopharma is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 93.06 M outstanding shares of which 199.85 K shares are at this time sold short in the market by investors with about 0.81 days to cover all shorted shares. More on YS Biopharma Co
Moving together with YS Biopharma Stock
| + | 0.87 | EQ | Equillium | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.8 | DMAC | DiaMedica Therapeutics | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.85 | VAXX | Vaxxinity | Fiscal Quarter End 31st of December 2023 | PairCorr |
Moving against YS Biopharma Stock
| - | 0.84 | KA | Kineta Inc | Symbol Change | PairCorr | |
| - | 0.58 | VANI | Vivani Medical | Fiscal Quarter End 31st of December 2023 | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
YS Biopharma Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. YS Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding YS Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Related Entity | SMIH (Summit Healthcare Acquisition) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SEC Filings | YS Biopharma Security & Exchange Commission EDGAR Reports | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Pharmaceutical Products (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering YS Biopharma report their recommendations after researching YS Biopharma's financial statements, talking to executives and customers, or listening in on YS Biopharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering YS Biopharma. The YS Biopharma consensus assessment is calculated by taking the average forecast from all of the analysts covering YS Biopharma. Strong Buy1 Opinion | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Piotroski F Score Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of YS Biopharma based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of YS Biopharma financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks. HealthyDetails
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Macroaxis Advice The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of YS Biopharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details Strong SellUndervalued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength YS Biopharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to YS Biopharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand YS Biopharma's financial leverage. It provides some insight into what part of YS Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
YS Biopharma Co (YS) is traded on NASDAQ Exchange in USA. It is located in null and employs 773 people. YS Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a market capitalization of 44.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate YS Biopharma's market, we take the total number of its shares issued and multiply it by YS Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. YS Biopharma is active under Biotechnology sector as part of Health Care industry. The entity has 93.06 M outstanding shares of which 199.85 K shares are at this time sold short in the market by investors with about 0.81 days to cover all shorted shares.
YS Biopharma generates negative cash flow from operations
Check YS Biopharma Probability Of Bankruptcy
OwnershipYS Biopharma Co shows a total of 93.06 Million outstanding shares. Almost 86.0 % of YS Biopharma outstanding shares are held by general public with 13.87 (percent) by institutions. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Ownership Allocation
Check YS Biopharma Ownership DetailsYS Biopharma Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of YS Biopharma jumping above the current price in 90 days from now is about 78.17%. The YS Biopharma Co probability density function shows the probability of YS Biopharma stock to fall within a particular range of prices over 90 days. Allowing for the 90-day total investment horizon YS Biopharma Co has a beta of -0.1643. This entails as returns on benchmark increase, returns on holding YS Biopharma are expected to decrease at a much lower rate. During the bear market, however, YS Biopharma Co is likely to outperform the market. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. YS Biopharma is significantly underperforming NYSE Composite.
Based on a normal probability distribution, the odds of YS Biopharma to move above the current price in 90 days from now is about 78.17 (This YS Biopharma Co probability density function shows the probability of YS Biopharma Stock to fall within a particular range of prices over 90 days) .
YS Biopharma Historical Income Statement
YS Biopharma Co Income Statement is one of the three primary financial statements used for reporting YS Biopharma's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of YS Biopharma revenue and expense. YS Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
View More FundamentalsYS Biopharma Stock Against Markets
Picking the right benchmark for YS Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in YS Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for YS Biopharma is critical whether you are bullish or bearish towards YS Biopharma Co at a given time. Please also check how YS Biopharma's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in YS Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bollinger Bands Now
Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon |
| All Next | Launch Module |
How to buy YS Biopharma Stock?
Before investing in YS Biopharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in YS Biopharma. To buy YS Biopharma stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of YS Biopharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase YS Biopharma stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located YS Biopharma Co stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased YS Biopharma Co stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as YS Biopharma Co, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy YS Biopharma Stock please use our How to Invest in YS Biopharma guide.
Already Invested in YS Biopharma Co?
The danger of trading YS Biopharma Co is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of YS Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than YS Biopharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile YS Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in YS Biopharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for YS Biopharma Stock analysis
When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 6.524 | Quarterly Revenue Growth (0.14) | Return On Equity (0.45) |
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.